![ukpds risk engine download ukpds risk engine download](https://www.bollfilter.com/uploads/_processed_/2/6/csm_03_Schiff_Lube_4stroke_04_00423e3737.jpg)
To evaluate the effect on metabolic control and CV risk evolution obtained by ‘add-on’ persistent sitagliptin treatment. It is to be underlined that this guidance has been updated and replaced by NICE guideline NG28. 4 As suggested by the NICE 2009 5 guideline, it should be assessed annually if the person is considered not to be at high CV risk. UKPDS RE 2 3 was selected because it provides the best risks estimates available for people with T2D. To validate the UK Prospective Diabetes Study (UKPDS) Risk Engine (RE) in a cohort of Italian participants with type 2 diabetes (T2D) without prespecified diabetes duration, with/without cardiovascular (CV) disease, treated with sitagliptin. The PERsistent Sitagliptin treatment & Outcomes (PERS&O) study 1 was a ‘real-world’ retrospective, observational, single-center study performed in a general hospital in Northern Italy in order The UKPDS RE score at 10 years and the BMI significantly improved during treatment with sitagliptin (p<0.001). When comparing patients treated with sitagliptin versus those stopping sitagliptin and switching to another antihyperglycemic drug, we detected a significant difference in the evolution of HbA1c in favor of patients who continued sitagliptin treatment. A significant improvement in HbA1c was evident during treatment with sitagliptin (p<0.01): the reduction was rapid (median HbA1c after 4–6 months: 7.5%) and continued at longer follow-up.
![ukpds risk engine download ukpds risk engine download](https://www.mdpi.com/jfmk/jfmk-03-00003/article_deploy/html/images/jfmk-03-00003-g002.png)
From Kaplan-Meier curves, the estimated median drug survival was 32.8 months when considering discontinuation for any cause and 58.4 months when considering discontinuation for loss of efficacy. Median follow-up from starting sitagliptin treatment was 5.6 years. Results At baseline, most patients were overweight or obese (median body mass index (BMI) (kg/m 2) 30.2) median HbA1c was 8.4% median fasting plasma glucose: 172 mg/dL median UKPDS RE score: 24.8%, being higher in men (median 30.2%) than in women (median 17.0%) as expected.